News
Aptar Pharma’s Twister®, a versatile DPI for fast growing markets Global solution provider of innovative and proven aerosol, injection and spray delivery systems for prescription drugs, Aptar Pharma Prescription Division will present Twister®, its latest Dry Powder Inhaler innovation, at the Pharmapack Europe tradeshow to be held in Paris, France, from February 13th to February 14th, 2013. READ MORE
Aptar Pharma unveils a multi-language website to meet local customers’ needs Global solution provider of innovative and proven aerosol, injection and spray delivery systems for biotech, healthcare and pharma products, Aptar Pharma expands its worldwide presence through an upgraded multi-language information resources website: ww.aptar.com/pharma READ MORE
Register now to attend the RDD Europe 2013 Scientific Conference to be held May 21-24, in Berlin, Germany The Respiratory Drug Delivery (RDD®) Europe 2013 scientific conference will welcome pulmonary and nasal drug delivery experts from all over the world to Berlin, May 21-24, 2013. The joint organizers of this prestigious event, RDD Online® and Aptar Pharma, announce the opening of registration at www.rddonline.com/rddeurope2013. READ MORE
Aptar Pharma Landmark® dose indicator chosen for new asthma combination therapy flutiform®, which uses an Aptar Pharma Landmark® dose indicator and metering valve, is now available in Germany and the UK. Aptar Pharma, World leader in the development and manufacturing of nasal and pulmonary drug delivery devices has developed a unique customized Dose Indicator for flutiform®. flutiform®, a SkyePharma product, is licensed to Mundipharma International Corporation Limited in Europe. READ MORE
Jean-Marc Pardonge appointed as new President of Aptar Pharma Prescription Division Jean-Marc Pardonge, 52 years old, has been appointed as the new President of Aptar Pharma’s Prescription Division, world leader in the development and manufacturing of nasal and pulmonary drug delivery devices. Jean-Marc Pardonge succeeds Salim Haffar, and becomes the new General Manager of Aptar Stelmi (the Stelmi company was recently acquired by Aptargroup)... READ MORE
Aptar Pharma Landmark® dose indicator chosen for allergic rhinitis ZETONNA™ (ciclesonide) Nasal Aerosol from Sunovion Pharmaceuticals Inc., equipped with an Aptar Pharma Landmark® dose indicator, is now available in the USA for the treatment of symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older. Louveciennes – France – August 1, 2012 - World leader in the development and manufacturing of nasal and pulmonary drug delivery devices, Aptar Pharma worked closely with Sunovion Pharmaceuticals for over six years to develop a unique customized Dose Indicator for the delivery of ZETONNA. The innovative actuator offers an alternative to conventional spray pump-based systems. READ MORE
Oval Medical Technologies signs key agreement with leading global pharmaceutical company Cambridge, UK. May 14th, 2012. Oval Medical Technologies Ltd. (“Oval”), the company developing the next generation of autoinjectors, today announced that they have entered into an agreement with a top ten global pharmaceutical company to evaluate one of their leading prescription drugs in Oval’s novel autoinjector technology. Under the terms of Agreement, the pharmaceutical company has the option to enter into a license and development agreement to jointly develop and commercialize an autoinjector product with Oval. READ MORE
Aptar Pharma’s clinical study confirms a major advance in Dry Powder Inhalers World leader in nasal and pulmonary drug delivery devices, Aptar Pharma will unveil the results of the latest patient-focused clinical studies using the Prohaler® Dry Powder Inhaler, at the upcoming RDD® (Respiratory Drug Delivery) scientific conference. RDD® 2012 will be held in Phoenix, Arizona, from May 15th-17th 2012. READ MORE
Aptar Pharma celebrates Asthma Day with a Twister™ of innovation World leader in the development and manufacturing of nasal and pulmonary drug delivery devices including inhalers for asthma, Aptar Pharma launches Twister™, a new versatile affordable capsule-based Dry Powder Inhaler (DPI) specifically targeting fast growing markets. READ MORE
Aptar Pharma Sublingual Unit-Dose Spray delivers INSYS THERAPEUTICS’ SUBSYS™ INSYS Therapeutics’ SUBSYS™, which uses an Aptar Pharma Sublingual Unit-Dose Spray (UDS) device, has been launched in the USA for breakthrough cancer pain in patients with cancer who are 18 years of age and older and who are already tolerant to opioid therapy. World leader in the development and manufacturing of alternate route drug delivery devices, Aptar Pharma worked closely with INSYS to develop a unique customized sublingual Unit-Dose Spray (UDS) device for the delivery of SUBSYS™. READ MORE
Aptar Pharma unveils eDevices, novel smart drug delivery devices for the future World leader in the development and manufacturing of nasal and pulmonary drug delivery devices, Aptar Pharma will present its latest innovation, eDevices, at the Pharmapack Europe tradeshow, to be held in Paris, France, from February 15th to February 16th, 2012. READ MORE
Aptar pharma expands presence in India with a new manufacturing site near Mumbai Aptar Pharma, world leader in the development and manufacturing of nasal and pulmonary drug delivery devices, today announces the opening of a new facility near Mumbai, India. READ MORE
Aptar Pharma’s Oro-Mucosal Spray Device chosen for spasticity in multiple sclerosis Sativex® Oromucosal Spray, which uses an Aptar Pharma spray pump, is the first approved cannabis-based prescription medicine to be launched in Germany in the field of spasticity in multiple sclerosis management. World leader in nasal and pulmonary drug delivery devices, Aptar Pharma worked closely with GW Pharmaceuticals to develop the mouth spray device which allows Sativex® (Delta-9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD)), a cannabinoid medicine, to be delivered to multiple sclerosis (MS) patients suffering from muscle spasticity. READ MORE
Aptar Pharma unveils DF30Plus, the New Optimized Metering Valve for HFA pMDIs World leader in the development and manufacturing of nasal and pulmonary drug delivery devices, Aptar Pharma will unveil its latest innovation, DF30Plus, at the Drug Delivery to the Lungs (DDL) scientific conference, to be held in Edinburgh, Scotland, from December 7th to December 9th, 2011. This new DF30Plus metering valve is the result of continuous improvement to the already world leading DF30 technology platform. READ MORE
AptarGroup acquires minority interest in Oval Medical Technologies Crystal Lake, Illinois - AptarGroup, Inc. (NYSE: ATR) today announced that it has acquired a minority interest in Oval Medical Technologies Limited and has secured a license regarding certain of Oval Medical Technologies’ intellectual property. READ MORE
Aptar Pharma is conference partner for the 5th Symposium on Nasal and Pulmonary Drug Delivery Aptar Pharma, world leader in the development and manufacturing of nasal and pulmonary drug delivery devices, is conference partner for the Indian Pharmaceutical Association's fifth symposium on “Nasal and Pulmonary Drug Delivery” with the theme of “Regulatory Challenges: The Way Forward”. This symposium will be held in Mumbai, India, on November 10th and 11th, 2011. READ MORE
Resounding Success for Aptar Pharma's Scientific Roundtable on Pain Management Aptar Pharma, the world leading supplier of innovative non-invasive drug delivery devices recently organized a scientific roundtable on "Sprays for pain management as an alternative to injection and other routes of administration". This international scientific forum was held in Paris, France on October 4th 2011. READ MORE
Advances in Respiratory Innovation and Technology Symposium a huge sucess Building upon the growing success of previous events, Aptar Pharma, the world leading supplier of innovative non-invasive drug delivery devices, collaborated with event host SFDA (Chinese State Food and Drug Administration) training center, to organize the fourth symposium on Advances in Respiratory Innovation and Technology. This was held in Shanghai, China from September 21 to September 23, 2011. READ MORE
Aptar Pharma's nasal spray device chosen for pain management SPRIX® (Kétorolac Trométhamine), Nasal Spray, which uses an Aptar Pharma nasal spray pump, is the first non-opioid nasal spray to hit the U.S. market in the field of pain management. World leader in the development and manufacturing of nasal and pulmonary drug delivery devices, Aptar Pharma worked closely with Roxro Pharma for over 7 years to develop the perfect nasal delivery system for SPRIX®. READ MORE
Record attendance at RDD Europe 2011 conference affirms continues strong interest in Pulmonary and Nasal Drug Delivery RDD® Europe 2011 in Berlin brought together pulmonary and nasal drug delivery experts from more than 30 countries for a unique exchange of knowledge, expertise, science and business networking. 465 delegates involved in pulmonary and nasal drug delivery attended the fourth RDD (Respiratory Drug Delivery) Europe conference in Germany last week. READ MORE
Pfeiffer and Valois announce the realignment of their pharmaceutical businesses under a common brand, Aptar Pharma, and unveil their new visual identities This market-focused realignment will make it even easier for customers to do business with Aptargroup through a wider and innovative range of products and services available under the new Aptar Pharma brand. READ MORE